Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance | Zendy

MingTain Lai | Zendy; Meizhen Feng | Zendy; Min Xu | Zendy; Winnie Ngo | Zendy; Tracy L. Diamond | Zendy; Carey Hwang | Zendy; Jay A. Grobler | Zendy; Daria J. Hazuda | Zendy; Ernest AsanteAppiah | Zendy

Open Access

Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance

Author(s) -

MingTain Lai,

Meizhen Feng,

Min Xu,

Winnie Ngo,

Tracy L. Diamond,

Carey Hwang,

Jay A. Grobler,

Daria J. Hazuda,

Ernest AsanteAppiah

Publication year - 2022

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02223-21

Subject(s) - dolutegravir , lamivudine , nucleoside reverse transcriptase inhibitor , emtricitabine , resistance mutation , reverse transcriptase inhibitor , reverse transcriptase , virology , zidovudine , drug resistance , biology , nucleoside , stavudine , pharmacology , human immunodeficiency virus (hiv) , virus , viral load , microbiology and biotechnology , genetics , antiretroviral therapy , hepatitis b virus , rna , viral disease , gene

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research